On Friday, December 8, the Colorado Prescription Drug Affordability Board (PDAB or Board) completed its first affordability review and unanimously voted that the selected drug, a cystic fibrosis drug called Trikafta, is “not unaffordable for Colorado consumers.” Trikafta is therefore not eligible for the imposition of an “upper payment limit” by the Board.
The PDAB also reviewed preliminary data presented by staff on the next two drugs under review, Genvoya (for HIV) and Enbrel (for autoimmune diseases), and plans to vote on their affordability, and then potentially on whether to set an upper payment limit, in February.
The PDAB’s December 8 Meeting
In the first two hours of the December 8 PDAB meeting, PDAB staff reviewed the draft Affordability Review Report for Trikafta with the Board and allowed Board members to ask questions and provide thoughts and feedback. In addition to PDAB…
Click here to view original post
